Date: 2015-04-17
Type of information: R&D agreement
Compound: cyclophilin-inhibiting molecules, NVP018/BC556, NVP014
Company: NeuroVive Pharmaceutical (Sweden) Isomerase Therapeutics (UK)
Therapeutic area: Cardiovascular diseases - Cerebrovascular diseases - Infectious diseases
Type agreement: R&D
development
commercialisation
Action mechanism:
Disease: traumatic brain injury, ischemic stroke, heart attack, antiviral indications
Details: * On June 12, 2013, NeuroVive Pharmaceutical, a swedish mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics for the product development and commercialization of the cyclophilin-inhibiting molecules that were recently acquired from Biotica. The collaboration will focus on cellular protection for traumatic brain injury and heart attack, as well as the new product NVP018/BC556 for antiviral indications. NVP018/BC556 is the primary drug candidate in NeuroVive´s new portfolio of potent cyclophilin inhibitors. It has undergone extensive preclinical evaluation and was developed for the treatment of Hepatitis C. The product shows a powerful effect against virus replication, and has an advantageous tolerability and pharmacokinetic profile. Cyclophilin inhibitors have a broad potential application range, and NeuroVive is currently evaluating the potential of NVP018/BC556 for antiviral indications. Development work will begin during the summer.
Financial terms:
Latest news: * On April 17, 2015, NeuroVive Pharmaceutical has announced that the company’s development project NVP014 for the treatment of ischemic stroke is entering a new phase in collaboration with UK partner Isomerase Therapeutics. The former collaboration with to-BBB of the Netherlands concluded at the end of 2014 and on the basis of the results obtained, NeuroVive is now developing new molecules and a more effective method for penetrating the blood-brain barrier. NeuroVive’s collaboration with to-BBB Technologies on the development of NVP014 for the treatment of ischemic stroke concluded at the end of 2014. Because to-BBB underwent restructuring just before the collaboration concluded and later went into liquidation, NeuroVive has chosen to bring the project to the next phase in collaboration with UK partner Isomerase Therapeutics. With the support of the chemistry platform NeuroVive acquired from Biotica in 2013, and new models for studies on penetration of the blood-brain barrier, the objective is to identify drug candidates for clinical development, mainly for the treatment of stroke. The earlier project with to-BBB was financed by an EU grant (Eurostars™) secured through Swedish VINNOVA, and VINNOVA has approved NeuroVive’s decision to continue development alongside Isomerase Therapeutics. Further funding is now being sought from sources including VINNOVA. The collaboration with Isomerase has already generated new lead compounds that are in pre-clinical evaluation.
